Related Experiment Videos
Prevention of cytomegalovirus disease in renal allograft recipients
1University of Minnesota Health Sciences Center, Department of Laboratory Medicine and Pathology, Minneapolis 55455.
Abstract:
Cytomegalovirus (CMV) disease in renal allograft recipients continues to cause morbidity, mortality and high medical expenses. In addition to damaging organs directly, CMV has been associated with allograft rejection, and bacterial, fungal and parasitic superinfections. Dramatic strides have been made in our efforts to prevent CMV disease. The prophylactic strategies have included passive immunization, interferon, vaccine, and antiviral agents. This article summarizes the experience to date in efforts to prevent CMV disease, emphasizing our current approach using high-dose oral acyclovir. It concludes with a review of potential future directions in prophylaxis with new antiviral agents alone or in combination.
Insights
Preventing cytomegalovirus (CMV) disease in kidney transplant patients is crucial. High-dose oral acyclovir is a current effective prophylactic strategy, with new antivirals offering future hope.
Area of Science:
- Nephrology
- Infectious Diseases
- Immunology
Background:
- Cytomegalovirus (CMV) disease poses significant risks for renal allograft recipients, leading to increased morbidity, mortality, and healthcare costs.
- CMV infection can directly damage organs and is linked to allograft rejection and secondary infections.
- Effective prevention strategies for CMV disease are essential in managing transplant patient outcomes.
Purpose of the Study:
- To summarize current and past prophylactic strategies against Cytomegalovirus (CMV) disease in renal transplant recipients.
- To highlight the efficacy and application of high-dose oral acyclovir as a primary prevention method.
- To review emerging antiviral agents and future directions in CMV prophylaxis.
Main Methods:
- Review of existing literature and clinical experience with various CMV disease prevention methods.
- Emphasis on the clinical data supporting the use of high-dose oral acyclovir.
- Exploration of ongoing research and development in antiviral therapies for CMV.
Main Results:
- Significant advancements have been made in preventing CMV disease through various prophylactic measures.
- High-dose oral acyclovir has demonstrated effectiveness in current clinical practice.
- Ongoing research is identifying new antiviral agents for improved prophylaxis.
Conclusions:
- Prophylaxis is key to reducing the burden of CMV disease in kidney transplant recipients.
- High-dose oral acyclovir represents a valuable tool in current CMV prevention protocols.
- Future strategies may involve novel antiviral agents, used alone or in combination, to further enhance protection.